Literature DB >> 24845114

Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series.

M H N Chagas1, A L Eckeli, A W Zuardi, M A Pena-Pereira, M A Sobreira-Neto, E T Sobreira, M R Camilo, M M Bergamaschi, C H Schenck, J E C Hallak, V Tumas, J A S Crippa.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Cannabidiol (CBD) is the main non-psychotropic component of the Cannabis sativa plant. REM sleep behaviour disorder (RBD) is a parasomnia characterized by the loss of muscle atonia during REM sleep associated with nightmares and active behaviour during dreaming. We have described the effects of CBD in RBD symptoms in patients with Parkinson's disease. CASES
SUMMARY: Four patients treated with CBD had prompt and substantial reduction in the frequency of RBD-related events without side effects. WHAT IS NEW AND
CONCLUSION: This case series indicates that CBD is able to control the symptoms of RBD.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  Parkinson's disease; cannabidiol; rapid eye movement sleep behaviour disorder

Mesh:

Substances:

Year:  2014        PMID: 24845114     DOI: 10.1111/jcpt.12179

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  61 in total

Review 1.  Current application of cannabidiol (CBD) in the management and treatment of neurological disorders.

Authors:  Brian Fiani; Kasra John Sarhadi; Marisol Soula; Atif Zafar; Syed A Quadri
Journal:  Neurol Sci       Date:  2020-06-16       Impact factor: 3.307

Review 2.  Evidence for the use of cannabinoids in Parkinson's disease.

Authors:  Carsten Buhmann; Tina Mainka; Georg Ebersbach; Florin Gandor
Journal:  J Neural Transm (Vienna)       Date:  2019-05-27       Impact factor: 3.575

3.  Oral Cannabidiol Does Not Convert to Δ8-THC or Δ9-THC in Humans: A Pharmacokinetic Study in Healthy Subjects.

Authors:  José Alexandre S Crippa; Antonio Waldo Zuardi; Jaime Eduardo Cecílio Hallak; Bruna Miyazawa; Sandra Aparecido Bernardo; Carmem Maria Donaduzzi; Silvane Guzzi; Wagner Alex Jann Favreto; Alline Campos; Maria Eugênia C Queiroz; Francisco S Guimarães; Patrícia Moura da Rosa Zimmermann; Letícia Mello Rechia; Volnei Jose Tondo Filho; Liberato Brum Junior
Journal:  Cannabis Cannabinoid Res       Date:  2020-02-27

Review 4.  Cannabis, Cannabinoids, and Sleep: a Review of the Literature.

Authors:  Kimberly A Babson; James Sottile; Danielle Morabito
Journal:  Curr Psychiatry Rep       Date:  2017-04       Impact factor: 5.285

Review 5.  Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies.

Authors:  Vamsi Reddy; Dayton Grogan; Meenakshi Ahluwalia; Évila Lopes Salles; Pankaj Ahluwalia; Hesam Khodadadi; Katelyn Alverson; Andy Nguyen; Srikrishnan P Raju; Pankaj Gaur; Molly Braun; Fernando L Vale; Vincenzo Costigliola; Krishnan Dhandapani; Babak Baban; Kumar Vaibhav
Journal:  EPMA J       Date:  2020-04-15       Impact factor: 6.543

Review 6.  Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.

Authors:  Nilson Carlos Ferreira Junior; Maurício Dos-Santos-Pereira; Francisco Silveira Guimarães; Elaine Del Bel
Journal:  Neurotox Res       Date:  2019-10-22       Impact factor: 3.911

Review 7.  Treatment of REM Sleep Behavior Disorder.

Authors:  Youngsin Jung; Erik K St Louis
Journal:  Curr Treat Options Neurol       Date:  2016-11       Impact factor: 3.598

Review 8.  Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?

Authors:  José Alexandre S Crippa; Jaime E C Hallak; Antônio W Zuardi; Francisco S Guimarães; Vitor Tumas; Rafael G Dos Santos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-01-31       Impact factor: 5.270

Review 9.  The therapeutic potential of cannabinoids for movement disorders.

Authors:  Benzi Kluger; Piera Triolo; Wallace Jones; Joseph Jankovic
Journal:  Mov Disord       Date:  2015-02-04       Impact factor: 10.338

10.  Dream enactment behavior: review for the clinician.

Authors:  Marc Baltzan; Chun Yao; Dorrie Rizzo; Ron Postuma
Journal:  J Clin Sleep Med       Date:  2020-11-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.